Given our strategic location in the heart of Maryland’s vibrant biotech landscape, and our unique access to speciality items such as Avastin and other injectables, Blue Door Pharma has become the “go to” distributor for many procurement officers.
Blue Door Pharma’s current customers are primarily US-based biotech companies with a general focus on pharmaceutical and biopharmaceutical research and development, and include some of the leaders in the industry, all who appreciate the value, quality, and service we provide.
Bevacizumab (Avastin), is an angiogenesis inhibitor, a drug that slows the growth of new blood vessels. It is used to treat various cancers, including colorectal, lung, breast (outside the USA), glioblastoma (USA only), kidney and ovarian. It was the first clinically available angiogenesis inhibitor in the United States.
Avastin was approved by the FDA for certain metastatic cancers. It received its first approval in 2004, for combination use with standard chemotherapy for metastatic colon cancer. It has since been approved for use in certain lung cancers, renal cancers, and glioblastoma multiforme of the brain.
Avastin is packaged as both in a 100 mg/4 mL, single use vial, and a 400 mg/16 mL, single use vial.